News & Updates

Pegfilgrastim on-body injectors (OBI) are as effective as traditional injection for the prevention of severe neutropaenia (SN), neutropaenic fever, and neutropaenia in breast cancer patients, reveals a study.

More treatment modifications secondary to adverse events appear necessary among obese patients receiving ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate indicated for the treatment of HER2-positive breast cancer, relative to nonobese counterparts, reports a study.

Women appear to be at higher risk of colorectal cancer death following adenoma removal, whereas men are at lower risk, as reported in a recent study.

An exercise and dietary lifestyle intervention regimen leads to better mobility outcomes among prostate cancer patients undergoing androgen deprivation therapy (ADT) as compared with standard-of-care management, a recent study has found. Moreover, social cognitive outcome measures seem to be predictive of such mobility outcomes.

The use of unopposed oestrogen in menopausal women may contribute to a heightened risk of cutaneous melanoma, a study has found.

The anti-CD19 chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel did not improve event-free survival (EFS) compared with standard care in patients refractory or who had progressed following first-line therapy for aggressive B-cell non-Hodgkin’s lymphoma, results of the phase III BELINDA trial showed.